Previous Page
12-03 :: March/April 2012
nanotimes
Companies Facts
Advertisement
13
Group Ltd., an established company that provides an extensive range of pharmaceutical services. In this agreement, Affymetrix has exclusive rights to distri- bute Almac’s Xcel™ array for research use in biomar- ker discovery for multiple disease areas, including cancer.
A
The Almac’s Xcel™ array is a microarray, built on the industry-standard Affymetrix’ GeneChip®
Human Ge-
nome U133 Plus 2.0 Array platform (RUO*), that has been optimized for RNA expression profiling from formalin fixed paraffin embedded (FFPE) samples.
board and leadership team. The Non-Executive Chairman, Mr. Gavin Rezos has agreed to move into the role of Executive Chairman and President, as the Company moves into the commercial licensing phase of the Reactive Surface Treatment (RST) technology and engages with the US Investment Community fol- lowing on from the recent OTC QX quotation in the US. This will require Mr Rezos to spend more time in the US and Europe overseeing the operational and commercial parts of the business and its network overseas. In addition we are also pleased to highlight the details and responsibilities of the current lea-
A
lexium International Group Limited (Alexium) (OTCQX: AXXIY) announced changes to its
ffymetrix, Inc. (NASDAQ: AFFX) has signed a global distribution agreement with Almac
dership team. There are no changes to the Board of Directors.